(Q38979908)

8 September 2017

NAMI-A is highly cytotoxic toward leukaemia cell lines: evidence of inhibition of KCa 3.1 channels (English)

1 reference

8 September 2017

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24975719%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Matteo Stefanini

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24975719%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Enzo Alessio

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24975719%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

author name string

Serena Pillozzi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24975719%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Mirco Ristori

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24975719%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Massimo D'Amico

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24975719%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Federica Scaletti

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24975719%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Andrea Becchetti

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24975719%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Annarosa Arcangeli

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24975719%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Luigi Messori

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24975719%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

language of work or name

English

0 references

publication date

1 August 2014

1 reference

8 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24975719%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

volume

43

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24975719%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

issue

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24975719%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

page(s)

12150-12155

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24975719%20AND%20SRC:MED&resulttype=core&format=json

Exploration of the medical periodic table: towards new targets

10 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1039%2FC4DT01356E

Pharmacological control of lung metastases of solid tumours by a novel ruthenium complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4DT01356E

Ruthenium antimetastatic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4DT01356E

The hydrolysis of the anti-cancer ruthenium complex NAMI-A affects its DNA binding and antimetastatic activity: an NMR evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4DT01356E

Blood concentration and toxicity of the antimetastasis agent NAMI-A following repeated intravenous treatment in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4DT01356E

Primary tumor, lung and kidney retention and antimetastasis effect of NAMI-A following different routes of administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4DT01356E

Recent developments in ruthenium anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4DT01356E

Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferrin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4DT01356E

A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4DT01356E

Metal-based antitumour drugs in the post genomic era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4DT01356E

Ruthenium complexes can target determinants of tumour malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4DT01356E

Influence of chemical stability on the activity of the antimetastasis ruthenium compound NAMI-A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4DT01356E

A kinetic study of the chemical stability of the antimetastatic ruthenium complex NAMI-A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4DT01356E

Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4DT01356E

Biochemical mechanisms of cisplatin cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4DT01356E

Arsenic trioxide induces G2/M growth arrest and apoptosis after caspase-3 activation and bcl-2 phosphorylation in promonocytic U937 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4DT01356E

Curcumin induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4DT01356E

Distinct cellular fates for KP1019 and NAMI-A determined by X-ray fluorescence imaging of single cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4DT01356E

Tumour cell uptake of the metastasis inhibitor ruthenium complex NAMI-A and its in vitro effects on KB cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4DT01356E

Uncoupling charge movement from channel opening in voltage-gated potassium channels by ruthenium complexes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4DT01356E

The ruthenium NO donor, [Ru(bpy)2(NO)SO3](PF6), inhibits inflammatory pain: involvement of TRPV1 and cGMP/PKG/ATP-sensitive potassium channel signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4DT01356E

Functional role of the slow activation property of ERG K+ channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4DT01356E

Targeting proliferation of chronic lymphocytic leukemia (CLL) cells through KCa3.1 blockade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4DT01356E

Ruthenium Anticancer Compounds: Challenges and Expectations

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4DT01356E

Ruthenium anticancer drugs and proteins: a study of the interactions of the ruthenium(III) complex imidazolium trans-[tetrachloro(dimethyl sulfoxide)(imidazole)ruthenate(III)] with hen egg white lysozyme and horse heart cytochrome c

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4DT01356E

A spectroscopic study of the reaction of NAMI, a novel ruthenium(III)anti-neoplastic complex, with bovine serum albumin

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4DT01356E

21 January 2018

Identifiers

DOI

10.1039/C4DT01356E

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24975719%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

1 reference